Cargando…
Longitudinal Modulation of Loco-Regional Immunity in Ovarian Cancer Patients Receiving Intraperitoneal Chemotherapy
SIMPLE SUMMARY: Insight into how immune cells change during chemotherapy can help develop new ways to support immune function and maximize treatment success in epithelial ovarian cancer (EOC). We aim to define the impact of chemotherapy on the tumor immune microenvironment by studying changes in imm...
Autores principales: | Suarez Mora, Adria, Strange, Mary, Fang, Yusi, Uygun, Ibrahim, Zhang, Lixin, Tseng, George C., Kalinski, Pawel, Edwards, Robert P., Vlad, Anda M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688312/ https://www.ncbi.nlm.nih.gov/pubmed/36428740 http://dx.doi.org/10.3390/cancers14225647 |
Ejemplares similares
-
PD-L1 biology in response to chemotherapy in vitro and in vivo in ovarian cancer
por: Grabosch, Shannon, et al.
Publicado: (2015) -
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
por: Riggs, McKayla J., et al.
Publicado: (2020) -
Hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer
por: Wu, Tao, et al.
Publicado: (2018) -
Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who have or have not received neoadjuvant chemotherapy for advanced ovarian cancer
por: Meghal, Trishala, et al.
Publicado: (2019) -
Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin
por: Markman, Maurie
Publicado: (2009)